HK1129837A1 - Cell-derived viral vaccines with low levels of residual cell dna - dna - Google Patents

Cell-derived viral vaccines with low levels of residual cell dna - dna

Info

Publication number
HK1129837A1
HK1129837A1 HK09107245.9A HK09107245A HK1129837A1 HK 1129837 A1 HK1129837 A1 HK 1129837A1 HK 09107245 A HK09107245 A HK 09107245A HK 1129837 A1 HK1129837 A1 HK 1129837A1
Authority
HK
Hong Kong
Prior art keywords
dna
cell
cell culture
low levels
residual
Prior art date
Application number
HK09107245.9A
Other languages
English (en)
Chinese (zh)
Inventor
．格雷格森
．科斯特
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1129837(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1129837A1 publication Critical patent/HK1129837A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK09107245.9A 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna HK1129837A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (fr) 2005-11-01 2006-11-01 Vaccins viraux derives de cellules, presentant de faibles niveaux d'adn cellulaire residuel

Publications (1)

Publication Number Publication Date
HK1129837A1 true HK1129837A1 (en) 2009-12-11

Family

ID=37969762

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09107245.9A HK1129837A1 (en) 2005-11-01 2009-08-07 Cell-derived viral vaccines with low levels of residual cell dna - dna
HK15108523.2A HK1207828A1 (en) 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15108523.2A HK1207828A1 (en) 2005-11-01 2015-09-01 Cell-derived viral vaccines with low levels of residual cell dna dna

Country Status (19)

Country Link
US (2) US10655108B2 (fr)
EP (3) EP2842572A1 (fr)
JP (5) JP5602366B2 (fr)
KR (1) KR20080081254A (fr)
CN (2) CN101365480B (fr)
AT (1) ATE494906T1 (fr)
AU (2) AU2006310171B2 (fr)
CA (1) CA2627971A1 (fr)
CY (1) CY1111378T1 (fr)
DE (1) DE602006019629D1 (fr)
DK (1) DK1951296T4 (fr)
EA (1) EA014062B1 (fr)
ES (2) ES2525518T3 (fr)
HK (2) HK1129837A1 (fr)
NZ (1) NZ567817A (fr)
PL (2) PL2301572T3 (fr)
PT (1) PT2301572E (fr)
SI (1) SI1951296T2 (fr)
WO (1) WO2007052163A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE494906T1 (de) * 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
DK2478916T3 (da) 2006-01-27 2020-06-15 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
ES2694805T7 (es) 2006-09-11 2021-10-21 Seqirus Uk Ltd Fabricación de vacunas contra virus de la gripe sin usar huevos
EP2185191B1 (fr) * 2007-06-27 2012-09-12 Novartis AG Vaccins antigrippaux à faible teneur en additifs
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CN101998990B (zh) 2008-03-18 2013-11-27 诺华股份有限公司 流感病毒疫苗抗原制备方法的改进
EP2361304A2 (fr) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Nouveau procédé
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
KR101800245B1 (ko) 2009-05-21 2017-11-22 노파르티스 아게 비-내인성 ｐｏｌ ｉ 프로모터를 사용하는 역 유전학
WO2011012999A1 (fr) 2009-07-31 2011-02-03 Novartis Ag Systemes de genetique inverse
EP2485764A4 (fr) 2009-10-09 2014-01-29 Childrens Medical Center Vaccin à cellules entières à dissociation sélective
EP2491117B2 (fr) 2009-10-20 2017-06-28 Novartis AG Procédés améliorés de génétique inverse pour recuperer des virus
US20130039943A1 (en) 2010-05-03 2013-02-14 Bruno Rene Andre Novel method
EP2566323A2 (fr) 2010-05-06 2013-03-13 Novartis AG Composés peroxydes organiques destinés à l'inactivation de microorganismes
CA2800150C (fr) 2010-05-21 2018-09-04 Novartis Ag Procede de rearrangement des genes du virus grippal
KR20220163497A (ko) 2010-06-01 2022-12-09 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
CA2801151A1 (fr) 2010-06-01 2011-12-08 Novartis Ag Concentration d'antigenes de vaccin par lyophilisation
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
US9517205B2 (en) 2010-08-20 2016-12-13 Seqirus UK Limited Soluble needle arrays for delivery of influenza vaccines
CA2828192A1 (fr) * 2011-02-25 2012-08-30 Novartis Ag Temoin positif interne exogene
WO2013098655A2 (fr) 2011-11-03 2013-07-04 Sentinext Therapeutics Sdn Bhd Antigènes et vaccins dirigés contre des entérovirus humains
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
WO2013131898A1 (fr) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination améliorée contre la grippe
EP2855701A1 (fr) 2012-06-04 2015-04-08 Novartis AG Test de sécurité amélioré
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
AU2014229255B2 (en) 2013-03-13 2018-12-13 Novartis Ag Influenza B virus reassortment
JP2016521282A (ja) 2013-05-10 2016-07-21 ノバルティス アーゲー インフルエンザワクチンにおけるナルコレプシーのリスクの回避
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (fr) 2013-06-06 2014-12-11 Novartis Ag Reassortiment du virus de la grippe
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
JP6373376B2 (ja) 2013-11-15 2018-08-15 ノバルティス アーゲー 残留細胞培養不純物の除去
JP6774149B2 (ja) * 2014-05-28 2020-10-21 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ エンテロウイルス感染に対する免疫原としてのウイルス粒子およびその生産
KR20180035807A (ko) 2015-06-26 2018-04-06 세퀴러스 유케이 리미티드 항원적으로 매치된 인플루엔자 백신
BR112018000296A2 (pt) 2015-07-07 2018-09-04 Seqirus UK Limited ensaios de potência de influenza
EP3184119A1 (fr) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatographie basée sur des stratégies de purification pour les virus de la rougeole basés sur un échafaudage
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
JP2023502650A (ja) 2019-11-18 2023-01-25 セキラス ピーティーワイ リミテッド 遺伝子再集合インフルエンザウイルスを産生するための方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (fr) * 1974-01-14 1977-07-15 Sandoz Ag
EP0251575B2 (fr) 1986-06-17 2002-11-13 Chiron Corporation Agents de diagnostic et vaccins pour l'hépatite delta, leur préparation et leur usage
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1999062546A1 (fr) * 1998-06-01 1999-12-09 Chiron Corporation Utilisation de polymeres d'acide hyaluronique pour une administration par les muqueuses d'antigenes vaccinaux
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
KR100922031B1 (ko) * 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2383105C (fr) 1999-09-24 2010-01-26 Smithkline Beecham Biologicals S.A. Vaccin intranasal contre les virus grippaux
EP1103610A1 (fr) 1999-11-26 2001-05-30 Introgene B.V. Production de vaccins de lignées de cellules mammifère immortalisées
WO2001041814A1 (fr) 1999-12-08 2001-06-14 Crucell Holland B.V. Technique d'administration d'adenovirus
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
JP2004536785A (ja) 2001-02-23 2004-12-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
CA2445120A1 (fr) 2001-04-27 2002-11-07 Glaxosmithkline Biologicals Sa Nouveau vaccin
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
WO2003091401A2 (fr) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Systeme multiplasmide de production de virus influenza
AU2003299244A1 (en) 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
CA2522379C (fr) * 2003-04-10 2012-10-23 Chiron Corporation Le coronavirus du syndrome respiratoire aigu grave
WO2004112831A2 (fr) 2003-05-28 2004-12-29 Wisconsin Alumni Research Foundation Virus influenza de recombinaison a titre eleve pour vaccins et therapie genique
EP1528101A1 (fr) 2003-11-03 2005-05-04 ProBioGen AG Lignées cellulaires aviaires immortalisées pour la production de virus
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
WO2005113756A1 (fr) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Methode
KR20070060049A (ko) 2004-05-20 2007-06-12 아이디 바이오메디칼 코포레이션 인플루엔자 백신의 제조방법
ES2386272T3 (es) * 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
US7670837B2 (en) 2004-12-23 2010-03-02 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
ATE494906T1 (de) * 2005-11-01 2011-01-15 Novartis Vaccines & Diagnostic Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna

Also Published As

Publication number Publication date
JP2016185988A (ja) 2016-10-27
WO2007052163A2 (fr) 2007-05-10
US11466257B2 (en) 2022-10-11
CN101365480A (zh) 2009-02-11
SI1951296T2 (sl) 2014-09-30
JP2020023557A (ja) 2020-02-13
ES2525518T3 (es) 2014-12-26
PL1951296T5 (pl) 2015-06-30
US20200377864A1 (en) 2020-12-03
PT2301572E (pt) 2014-12-22
NZ567817A (en) 2012-01-12
EA014062B1 (ru) 2010-08-30
ATE494906T1 (de) 2011-01-15
EP1951296B2 (fr) 2014-07-23
KR20080081254A (ko) 2008-09-09
BRPI0618094A8 (pt) 2017-08-22
US20090304729A1 (en) 2009-12-10
PL1951296T3 (pl) 2011-09-30
EA200801221A1 (ru) 2008-10-30
JP2009513694A (ja) 2009-04-02
HK1207828A1 (en) 2016-02-12
EP2842572A1 (fr) 2015-03-04
SI1951296T1 (sl) 2011-04-29
JP2011256209A (ja) 2011-12-22
CY1111378T1 (el) 2015-08-05
CN104474543A (zh) 2015-04-01
ES2359214T3 (es) 2011-05-19
EP1951296B1 (fr) 2011-01-12
CA2627971A1 (fr) 2007-05-10
ES2359214T5 (es) 2014-10-08
EP1951296A2 (fr) 2008-08-06
EP2301572A1 (fr) 2011-03-30
US10655108B2 (en) 2020-05-19
AU2006310171B2 (en) 2011-02-17
AU2011201968B2 (en) 2014-08-28
BRPI0618094A2 (pt) 2011-08-16
AU2006310171A1 (en) 2007-05-10
WO2007052163A3 (fr) 2007-09-07
CN101365480B (zh) 2014-11-05
JP2014198726A (ja) 2014-10-23
JP7049761B2 (ja) 2022-04-07
EP2301572B1 (fr) 2014-09-10
PL2301572T3 (pl) 2015-02-27
AU2011201968A1 (en) 2011-05-19
DK1951296T4 (da) 2014-09-01
DK1951296T3 (da) 2011-03-28
DE602006019629D1 (de) 2011-02-24
JP6639077B2 (ja) 2020-02-05
JP5602366B2 (ja) 2014-10-08

Similar Documents

Publication Publication Date Title
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
WO2007024941A3 (fr) Vaccin polyvalent
WO2011015656A3 (fr) Composition pour le traitement d'une infection par le virus de l'hépatite b
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
WO2012061815A3 (fr) Particules de type viral de glycoprotéine de la rage (vlp)
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
WO2010019262A3 (fr) Vaccin polyvalent
WO2008115281A3 (fr) Composés de traitement d'infections virales
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
WO2008039267A3 (fr) Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2009026465A3 (fr) Composition et procédés de fabrication et d'utilisation de protéines de la grippe
EA201170533A1 (ru) Высокодиспергируемый диоксид кремния для резин и способ его получения
WO2008054481A3 (fr) Meilleures compositions de virus influenza inactivé
WO2011082388A3 (fr) Vaccins à base d'adn infectieux contre le virus du chikungunya
EP2078083A4 (fr) Nouveau virus de la grippe canine et vaccin correspondant
WO2010001409A3 (fr) Composition de vaccin utile pour les infections par le virus de l'hépatite b et par le papillomavirus humain et son procédé de préparation
WO2010095041A3 (fr) Compositions, procédés et kits pour traiter des infections par le virus de la grippe
WO2009029384A3 (fr) Composés utilisés dans le traitement de l'hépatite c
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
WO2008048344A3 (fr) Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
WO2008115314A3 (fr) Vecteur vaccinal flavivirus contre le virus de la grippe
WO2008124176A3 (fr) Formes solubles et ancrées sur membrane de protéines de sous-unité du virus lassa
WO2007082734A3 (fr) Vaccin anti-grippal
TW200531701A (en) Method of vaccination against testicular BVDV infection